Teva Finds Relief In US Opioid Crisis Settlement, Updates Long-Term Objectives :: Scrip
The Collapse of Teva, the Israeli giant generic drug company – a case study in strategy and intelligence
Teva Pays $420 Million to End Generic-Drug Securities Suit (1)
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Nobody Thought It Would Come to This': Drug Maker Teva Faces a Crisis - The New York Times
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Avoids Bankruptcy, Huge Upside (NYSE:TEVA) | Seeking Alpha
Is A Fall Imminent For Teva Stock After Its Recent Rally? | Trefis
Teva to pay New York $500M for role in opioid crisis - POLITICO
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma
Teva reaches $523 million deal to settle opioid lawsuit with New York | CNN Business
Nobody Thought It Would Come to This': Drug Maker Teva Faces a Crisis - The New York Times
Teva puts further $468m aside for opioid settlements | Financial Times
Teva Pharmaceuticals Will Pay Up To $523 Million In New York For Opioid Settlement
'Nobody Thought It Would Come to This': Drug Maker Teva Faces a Crisis - The New York Times
Teva sells its only manufacturing plant in Russia
Teva reaches $4.25B deal to settle opioid lawsuits | The Hill
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva's Turnaround: Is It Ever Or Never?
Teva Pharmaceuticals Found Liable For Opioid Crisis by Jury, Trial Will Determine Penalty
